massive support , page-2

Another box ticked by Dendreon. Both PRR & DNDN are based out of Seattle & hopefully are talking to the same FDA board. After DNDN gets its approval, it goes to commercial phase & needs to find a marketing partner for US & overseas market in early 2010.

Once Prima finish their current Phase-2a trials, they go to Phase 3. Whats interesting is after their Phase-1 trial, they said in an presentation that the trial had exceeded all internal hurdles & excited the scientific community (April presentation).

And here's a link to DNDN's Investor meeting transcript

---------------------------------------------------------
Dendreon to submit Provenge for FDA OK in November
Thursday, September 24, 2009, 9:03am PDT

Dendreon Corp. said it will submit its Provenge prostate cancer drug to the U.S. Food and Drug Administration by the middle of November.

At an analyst meeting in New York Thursday, the Seattle biotech (NASDAQ: DNDN) said it expects to commercialize the drug by the middle of next year “to the many men with metastatic castrate-resistant prostate cancer who currently have few appealing treatment options.”

Dendreon officials also said that it will launch Provenge production from its New Jersey manufacturing facility. In the second half of 2011, additional manufacturing facilities in Los Angeles and Atlanta will begin producing the drug.

The company added that it plans to initiate a clinical trial of its Neuvenge drug that will target bladder cancer in late 2010 or early 2011.

Earlier this summer, Dendreon said it plans to more than double the size of its headquarters near downtown Seattle and is seeking approximately a quarter-million square feet of office and laboratory space along the waterfront or in the South Lake Union neighborhood.